Executive Summary
Meldex International is a specialty pharmaceutical and healthcare business that uses its XGEL polymer technologies to develop and enhance medicines and healthcare products. Meldex International develops innovative delivery technology using its XGEL ingestible and non-ingestible polymer platforms to enhance its own pharmaceutical and healthcare products and those of its partners. The Company has product development agreements and strategic alliances with several global pharmaceutical companies including MC BioPolymer Inc. Meldex International is an international operation. It has sales and marketing infrastructure in the UK, France, Italy and the USA; product development in the UK and USA and a product portfolio of branded and generic pharmaceutical and healthcare products in France, Italy, UK and US.
The Company had year to December 2007 revenue and EBITDA of £27.1m and made an operating loss of -£231k.
Company History
Current Events
Business Model
Products/Services
Segments/Customers
Production/Operations
Distribution/Routes to Market
Market & Competition
Market Share
Main Competitors
Competitive Strengths and Weaknesses
Management
Financials
Profit & Loss
Balance sheet
Cashflow
Valuation
Comparable Companies
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
